Company
Neurocrine Biosciences, Inc (NASDAQ:NBIX)’s 12-Month Price Target Currently Stands At 168
In last trading session, Neurocrine Biosciences, Inc (NASDAQ:NBIX) saw 0.85 million shares changing hands with its beta currently measuring 0.24. Company’s recent per share price